Steiner & Co., Deutsche Arzneimittel GmbH & Co. KG, Wallenroder Strasse 12-14, 13435 Berlin, Germany.
J Pharm Biomed Anal. 2013 May 5;78-79:65-74. doi: 10.1016/j.jpba.2013.01.032. Epub 2013 Jan 31.
A stability-indicating ultra high performance liquid chromatographic (UHPLC) method has been developed for purity testing of ebastine and its pharmaceutical formulations. Successful chromatographic separation of the API from impurities was achieved on a Waters Acquity UPLC BEH C18, 50 mm × 2.1 mm, 1.7 μm particle size column with gradient elution of 10 mM acetate buffer pH 6.2 and a mixture of acetonitrile/2-propanol (1:1) as the mobile phase. Incorporating Quality by Design (QbD) principles to the method development approach by using the chromatography modeling software DryLab4 allows the visualization of a "Design Space", a region in which changes to method parameters will not significantly affect the results as defined in the ICH guideline Q8 (R2). A verification study demonstrated that the established model for Design Space is accurate with a relative error of prediction of only 0.6%. The method was fully validated for specificity, linearity, accuracy and precision, and robustness in compliance to the ICH guideline Q2 (R1). The method was found to be linear in the concentration range from the quantification limit (LOQ) to 125% of the specification limit for ebastine and each of the impurities with correlation coefficients of not less than 0.999. The recovery rate was between 98.15 and 100.30% for each impurity. The repeatability and intermediate precision (RSD) were less than 3.2% for ebastine and each of the impurities. The robustness of the developed method was studied by varying the six parameters: gradient time, temperature, ternary composition of the eluent, flow rate and start and end concentration of the gradient at 3 levels (+1, 0, -1). The resulting 729 experiments were performed in silico from the previously constructed model for Design Space and showed that the required resolution of 2.0 can be reached in all experiments. To prove the stability-indicating performance of the method, forced degradation (acid and base hydrolysis, oxidation, photolytic and thermal stress conditions) of ebastine was carried out. Baseline separation could be achieved for all peaks of the impurities, the degradation products and the API. Total run time was only 4 min, which is an impressive 40-fold increase in productivity in comparison to the method published in the Ph. Eur. monograph and allowed purity testing of more than 360 samples per day.
已开发出一种稳定性指示型超高效液相色谱(UHPLC)方法,用于检测依巴斯汀及其药物制剂的纯度。在 Waters Acquity UPLC BEH C18、50mm×2.1mm、1.7μm 粒径柱上,采用 10mM 乙酸缓冲液 pH6.2 和乙腈/2-丙醇(1:1)混合物作为流动相进行梯度洗脱,成功实现了 API 与杂质的分离。通过在方法开发过程中使用色谱建模软件 DryLab4 采用质量源于设计(QbD)原则,可以直观地看到“设计空间”,在此空间中,方法参数的变化不会对 ICH 指南 Q8(R2)定义的结果产生显著影响。验证研究表明,所建立的设计空间模型准确,预测相对误差仅为 0.6%。该方法已完全按照 ICH 指南 Q2(R1)进行了专属性、线性、准确性和精密度以及稳健性验证。该方法对依巴斯汀及其各杂质在定量限(LOQ)至规格限 125%的浓度范围内均呈线性,相关系数均不小于 0.999。每个杂质的回收率在 98.15%至 100.30%之间。依巴斯汀及其各杂质的重复性和中间精密度(RSD)均小于 3.2%。通过改变梯度时间、温度、洗脱剂三元组成、流速以及梯度的起始和结束浓度这 6 个参数,研究了开发方法的稳健性,在 3 个水平(+1、0、-1)下进行了 729 次实验。这些实验都是通过先前构建的设计空间模型进行的虚拟实验,结果表明,在所有实验中都可以达到所需的 2.0 分辨率。为了证明该方法的稳定性指示性能,对依巴斯汀进行了强制降解(酸和碱水解、氧化、光解和热应力条件)。可以实现所有杂质、降解产物和 API 峰的基线分离。总运行时间仅为 4 分钟,与欧洲药典专论中公布的方法相比,生产效率提高了 40 倍,每天可检测 360 多个样品。